SCHEDULE 13G/A: Vanguard Group Maintains Significant Passive Stake in Ionis Pharmaceuticals, Disclosing 10.43% Ownership
Beneficial Ownership Disclosure
The Vanguard Group has filed an Amendment No. 13 to its Schedule 13G, reporting a 10.43% beneficial ownership stake in Ionis Pharmaceuticals Inc. as of December 31, 2024.
Summary
- The Vanguard Group, an investment adviser, reported beneficial ownership of 16,472,539 shares of Common Stock in Ionis Pharmaceuticals Inc.
- This ownership represents 10.43% of the class of securities.
- The filing is an Amendment No. 13 to a Schedule 13G, indicating an update to a previously reported passive stake.
- Vanguard Group holds 0.00 shares with sole voting power, 69,305 shares with shared voting power, 16,225,634 shares with sole dispositive power, and 246,905 shares with shared dispositive power.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a neutral, factual disclosure of beneficial ownership by a passive institutional investor. It contains no positive or negative operational or financial news about the issuer.
Future Outlook
This document does not contain any forward-looking statements or guidance from Ionis Pharmaceuticals Inc. or The Vanguard Group regarding the issuer's future performance.
Management Comments
- The Vanguard Group certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing is a routine disclosure by a large institutional investor, The Vanguard Group, indicating its passive ownership stake in Ionis Pharmaceuticals Inc. It reflects standard portfolio management and does not imply any specific strategic move related to the biotechnology or pharmaceutical industry trends beyond a continued investment in the company.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a large, passive investment by The Vanguard Group.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date) |
| 01/08/2025 | Date of signing the Schedule 13G amendment |
Keywords
Ionis Pharmaceuticals, Vanguard Group, Schedule 13G, beneficial ownership, institutional investor, common stock, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.